What Is a Hair Growth Active
A hair growth active is a bioactive compound that targets the hair follicle to extend the anagen phase, increase hair shaft diameter, or stimulate dermal papilla cell proliferation. The global market for hair growth actives was valued at approximately $4.2 billion in 2024 and is projected to grow at a compound annual growth rate of around 5.8% through 2030, according to Grand View Research. Key actives include minoxidil, finasteride, peptides, caffeine, and plant-derived extracts such as saw palmetto and rosemary oil. Market data from Grand View Research and Forbes show that minoxidil remains the most clinically proven over-the-counter active for androgenetic alopecia.
Leading Companies and Formulation Trends
Major companies active in hair growth formulations include Pfizer, Johnson & Johnson, L'Oréal, and Procter & Gamble, which invest heavily in peptide and scalp-care technologies. Pfizer markets Rogaine, while Johnson & Johnson's Neutrogena T/Gel and L'Oréal's Serie Expert lines incorporate active ingredients targeting follicle health. In 2024, L'Oréal launched a new peptide-based scalp serum targeting the Wnt signaling pathway, citing in-vitro data on hair shaft thickness. SEC filings from L'Oréal highlight R&D expenditure increases for personal care active ingredients.
Peptides and Plant Actives
Peptide-based actives such as copper peptides and myristoyl pentapeptide-17 are increasingly used in professional and at-home devices. Forbes reports on peptide adoption notes that clinical studies show a 12% increase in hair count after 24 weeks of use in specific formulations.
Clinical Evidence and Regulatory Status
Minoxidil 5% solution is FDA-approved for androgenetic alopecia in men and women, with pivotal trials showing a 20% increase in hair count versus placebo at 48 weeks. Finasteride 1mg is FDA-approved for male pattern hair loss and requires a prescription, with clinical data showing a 30% increase in hair count over 12 months. FDA drug approval pages list minoxidil and finasteride as approved prescription and OTC actives. A 2023 systematic review on hair growth actives concludes that low-level laser therapy and platelet-rich plasma show moderate evidence for hair density improvement.